BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
for Clinical Stage III Cutaneous Melanoma AJCC v8
Drug: Cabozantinib
Sites in Livonia, Ypsilanti +204 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT05136196·Phase 2·Recruiting·Listed Nov 2021